{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:51Z","timestamp":1792518051906,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"DOI":"10.1038\/s41434-026-00648-8","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:09:03Z","timestamp":1792256943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statistical correlation between strength and mini-dystrophin expression in skeletal muscle after an rAAV9-mini-dystrophin gene therapy candidate in DMDmdx rats"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6694-5574","authenticated-orcid":false,"given":"J. M.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4164-502X","authenticated-orcid":false,"given":"A.","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-2300","authenticated-orcid":false,"given":"C.","family":"Le Guiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lafoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Binks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Neelakantan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Farrokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-5427","authenticated-orcid":false,"given":"H.","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"648_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4.","journal-title":"Cell"},{"key":"648_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJ, Kunkel LM. The pathogenesis and therapy of muscular dystrophies. Annu Rev Genom Hum Genet. 2015;16:281\u2013308. https:\/\/doi.org\/10.1146\/annurev-genom-090314-025003.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"648_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1590\/0004-282X20190088","volume":"77","author":"LC Werneck","year":"2019","unstructured":"Werneck LC, Lorenzoni PJ, Ducci RD, Fustes OH, Kay CSK, Scola RH. Duchenne muscular dystrophy: an historical treatment review. Arq Neuropsiquiatr. 2019;77:579\u201389. https:\/\/doi.org\/10.1590\/0004-282X20190088.","journal-title":"Arq Neuropsiquiatr"},{"key":"648_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1515\/BC.1999.078","volume":"380","author":"H Bueler","year":"1999","unstructured":"Bueler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem. 1999;380:613\u201322. https:\/\/doi.org\/10.1515\/BC.1999.078.","journal-title":"Biol Chem"},{"key":"648_CR5","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/mt.2008.207","volume":"16","author":"Y Yue","year":"2008","unstructured":"Yue Y, Ghosh A, Long C, Bostick B, Smith BF, Kornegay JN, et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole-body skeletal muscle transduction in dogs. Mol Ther. 2008;16:1944\u201352. https:\/\/doi.org\/10.1038\/mt.2008.207.","journal-title":"Mol Ther"},{"key":"648_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","volume":"8","author":"SQ Harper","year":"2002","unstructured":"Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253\u201361. https:\/\/doi.org\/10.1038\/nm0302-253.","journal-title":"Nat Med"},{"key":"648_CR7","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/mt.2010.94","volume":"18","author":"JN Kornegay","year":"2010","unstructured":"Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther. 2010;18:1501\u20138. https:\/\/doi.org\/10.1038\/mt.2010.94.","journal-title":"Mol Ther"},{"key":"648_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105. https:\/\/doi.org\/10.1038\/ncomms16105.","journal-title":"Nat Commun"},{"key":"648_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jor.20781","volume":"27","author":"B Wang","year":"2009","unstructured":"Wang B, Li J, Fu FH, Xiao X. Systemic human minidystrophin gene transfer improves functions and lifespan of dystrophin- and dystrophin\/utrophin-deficient mice. J Orthop Res. 2009;27:421\u20136. https:\/\/doi.org\/10.1002\/jor.20781.","journal-title":"J Orthop Res"},{"key":"648_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1815","volume":"15","author":"SM Birch","year":"2023","unstructured":"Birch SM, Lawlor MW, Conlon TJ, Guo LJ, Crudele JM, Hawkins EC, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med. 2023;15:eabo1815. https:\/\/doi.org\/10.1126\/scitranslmed.abo1815.","journal-title":"Sci Transl Med"},{"key":"648_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.omtm.2023.05.017","volume":"30","author":"C Le Guiner","year":"2023","unstructured":"Le Guiner C, Xiao X, Larcher T, Lafoux A, Huchet C, Toumaniantz G, et al. Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy. Mol Ther Methods Clin Dev. 2023;30:30\u201347. https:\/\/doi.org\/10.1016\/j.omtm.2023.05.017.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"648_CR12","doi-asserted-by":"publisher","first-page":"e110371","DOI":"10.1371\/journal.pone.0110371","volume":"9","author":"T Larcher","year":"2014","unstructured":"Larcher T, Lafoux A, Tesson L, Remy S, Thepenier V, Francois V, et al. Characterization of dystrophin-deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE. 2014;9:e110371. https:\/\/doi.org\/10.1371\/journal.pone.0110371.","journal-title":"PLoS ONE"},{"key":"648_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41434-021-00300-7","volume":"29","author":"V Farrokhi","year":"2022","unstructured":"Farrokhi V, Walsh J, Palandra J, Brodfuehrer J, Caiazzo T, Owens J, et al. Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. Gene Ther. 2022;29:608\u201315. https:\/\/doi.org\/10.1038\/s41434-021-00300-7.","journal-title":"Gene Ther"},{"key":"648_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1474-4422(26)00036-0","volume":"25","author":"F Muntoni","year":"2026","unstructured":"Muntoni F, Nascimento A, Shin J, Guglieri M, Stettner GM, Veerapandiyan A, et al. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2026;25:245\u201355. https:\/\/doi.org\/10.1016\/S1474-4422(26)00036-0.","journal-title":"Lancet Neurol"},{"key":"648_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial. Muscle Nerve. 2024;69:93\u20138. https:\/\/doi.org\/10.1002\/mus.27955.","journal-title":"Muscle Nerve"},{"key":"648_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/joa.13547","volume":"240","author":"AA Castro","year":"2022","unstructured":"Castro AA, Karakostis FA, Copes LE, McClendon HE, Trivedi AP, Schwartz NE, et al. Effects of selective breeding for voluntary exercise, chronic exercise, and their interaction on muscle attachment site morphology in house mice. J Anat. 2022;240:279\u201395. https:\/\/doi.org\/10.1111\/joa.13547.","journal-title":"J Anat"},{"key":"648_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pri.520","volume":"17","author":"E Scott","year":"2012","unstructured":"Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, et al. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int. 2012;17:101\u20139. https:\/\/doi.org\/10.1002\/pri.520.","journal-title":"Physiother Res Int"},{"key":"648_CR18","unstructured":"Mercuri E, Nascimento A, Shin JH, Stettner GM, Guglieri M, Veerapandiyan A, et al. CIFFREO, a phase 3, randomized, double-blind, placebo-controlled study of fordadistrogene movaparvovec in Duchenne muscular dystrophy (DMD). Poster presented at: 29th Annual Congress of the World Muscle Society; October 8-12, 2024; Prague, Czechia."},{"key":"648_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2025.1569289","volume":"16","author":"K Raghavan","year":"2025","unstructured":"Raghavan K, Ikewaki N, Preethy S, Abraham SJK. Improving the therapeutic efficacy of gene therapy for Duchenne muscular dystrophy (DMD) by evaluating and managing inflammation. Front Genet. 2025;16:1569289. https:\/\/doi.org\/10.3389\/fgene.2025.1569289.","journal-title":"Front Genet"},{"key":"648_CR20","doi-asserted-by":"publisher","first-page":"e8647","DOI":"10.1371\/journal.pone.0008647","volume":"5","author":"GL Walmsley","year":"2010","unstructured":"Walmsley GL, Arechavala-Gomeza V, Fernandez-Fuente M, Burke MM, Nagel N, Holder A, et al. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One. 2010;5:e8647. https:\/\/doi.org\/10.1371\/journal.pone.0008647.","journal-title":"PLoS One"},{"key":"648_CR21","doi-asserted-by":"publisher","unstructured":"Sui T, Lau YS, Liu D, Liu T, Xu L, Gao Y, et al. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR\/Cas9. Dis Model Mech. 2018;11:dmm032201. https:\/\/doi.org\/10.1242\/dmm.032201.","DOI":"10.1242\/dmm.032201"},{"key":"648_CR22","doi-asserted-by":"publisher","unstructured":"Stirm M, Fonteyne LM, Shashikadze B, Lindner M, Chirivi M, Lange A, et al. A scalable, clinically severe pig model for Duchenne muscular dystrophy. Dis Model Mech. 2021;14:dmm049285. https:\/\/doi.org\/10.1242\/dmm.049285.","DOI":"10.1242\/dmm.049285"},{"key":"648_CR23","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1016\/j.cell.2024.08.041","volume":"187","author":"S Ren","year":"2024","unstructured":"Ren S, Fu X, Guo W, Bai R, Li S, Zhang T, et al. Profound cellular defects contribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy. Cell. 2024;187:6669\u201386.e6616. https:\/\/doi.org\/10.1016\/j.cell.2024.08.041.","journal-title":"Cell"},{"key":"648_CR24","doi-asserted-by":"publisher","unstructured":"Fernandez-Costa JM, Tejedera-Vilafranca A, Fernandez-Garibay X, Ramon-Azcon J. Muscle-on-a-chip devices: a new era for in vitro modelling of muscular dystrophies. Dis Model Mech. 2023;16:dmm050107. https:\/\/doi.org\/10.1242\/dmm.050107.","DOI":"10.1242\/dmm.050107"},{"key":"648_CR25","unstructured":"FDA. Three-Dimensional (3D) Cell Culture (Microphysiological) Platforms as Drug Development Tools. 2021. fda.gov\/drugs\/regulatory-science-action\/three-dimensional-3d-cell-culture-microphysiological-platforms-drug-development-tools."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00648-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:21Z","timestamp":1792515741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00648-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":25,"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00648-8","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AIM, JMW, VF, SN and HN are employees of Pfizer. JO and MB were employees of Pfizer at the time of the study. CLG is a co-author of a patent for systemic treatment of dystrophic pathologies (EP3044319A1, dated June 27, 2014).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}